Healius Needs Longer in Recovery Room -- Market Talk

Dow Jones

2025/08/25

0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that "sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing." Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

August 24, 2025 21:01 ET (01:01 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562229309"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562229309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562229309?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 09:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562229309","market":"us","top_or_hot":-1,"title":"Healius Needs Longer in Recovery Room -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius Needs Longer in Recovery Room -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius Needs Longer in Recovery Room -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-25 09:01</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 24, 2025 21:01 ET (01:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7509","symbol_name":"中概股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562229309","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562229309","pubTimestamp":1756083660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7509":"中概股","BK7501":"新冠治疗股","BK7124":"保健护理服务","HLS.AU":"HEALIUS LTD"},"translate_title":"Healius需要在恢复室呆更长时间——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"0101 GMT - Pathology services provider Healius is showing signs of life after a rough patch, but Morgans isn't ready to turn bullish on its stock. Healius reported steady progress on its strategy to lift operating margins into the high-single-digit percentage range by end-FY 2027 through raising revenue and reducing costs. But analyst Derek Jellinek concludes that \"sustainable earnings growth is still questionable, execution risk is high, and there are plenty of uncertainties, including fair work commission proposals and recent Medicare changes to vitamin B12 and urine testing.\" Morgans retains a hold call on Healius's stock, and cuts its price target by 9.4% to A$0.87/share. Healius is unchanged at A$0.83. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 24, 2025 21:01 ET (01:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}